Answers are grounded in this paper and cite their sources.
Presented herein is the case report of a 46-year-old male with underlying G6PD deficiency who experienced dyspnea, radiographic pulmonary infiltrates, and unexplained tachycardia while on both FOLFOX chemotherapy and febrile neutropenia prophylaxis with G-CSF support. The proposed mechanism of illness was oxidativestress induced pulmonary toxicity mediated by oxaliplatin, G-CSF, and his underlying G6PD deficiency. He was treated through stopping all active chemotherapy agents and initiating oral steroids and nebulized N-acetylcystine. Within five weeks his symptoms had significantly improved, including a near-complete resolution of pulmonary infiltrates. This case report serves to review a general approach to drug-induced pneumonitis, and concurrently highlights the clinical significance of G6PD deficiency in routine patient care. In an increasingly global population, G6PD deficiency should be screened for in at-risk populations to optimize patient outcomes, including cancer patients.
No takes yet. Share an insight, caveat, or question.
Strum et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: